A major new study suggests that weight-loss injections such as Ozempic and Wegovy are rapidly changing how obesity is treated, while interest in weight-loss surgery is falling sharply.
For decades, bariatric surgery was considered one of the main medical options for people with severe obesity. These procedures physically reduce the size of the stomach or change how food moves through the digestive system, helping patients eat less and lose large amounts of weight.
Bariatric surgery has often helped improve serious health conditions linked to obesity, including type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea.
However, surgery is invasive, expensive, and requires recovery time. Some patients are also afraid of complications or permanent changes to the body.
Now, newer weight-loss medications are offering another option.
According to a new study published in JAMA Surgery, the use of GLP-1 medications surged by more than 140% between 2022 and 2024, while bariatric surgery use dropped by more than one-third.
Researchers analyzed insurance records from 11.7 million people in the United States who had obesity, overweight, or diabetes.
The findings reveal how rapidly public interest is shifting toward medication-based weight loss.
GLP-1 drugs include medications such as Ozempic, Wegovy, and Mounjaro. These drugs were originally developed to help control diabetes, but researchers soon discovered that many patients also lost substantial amounts of weight.
The medications work by copying a natural hormone called GLP-1, which helps regulate hunger and blood sugar after meals.
When the drugs activate GLP-1 receptors, the stomach empties more slowly. This helps people feel full more quickly and stay full longer after eating.
The medications also stimulate insulin release when blood sugar rises, improving diabetes control.
Together, these effects can lead to major weight loss and improvements in several obesity-related health problems.
Many people view these medications as easier and less frightening than surgery because they do not involve hospital operations or permanent anatomical changes.
The study showed just how dramatic the shift has become.
Nearly 10% of eligible patients chose GLP-1 medications during the study period, while only about 0.4% underwent bariatric surgery.
Researchers found that surgery rates steadily declined over the three-year period. The drop became even faster in 2024 after newer medications such as tirzepatide became more widely available.
The growing popularity of GLP-1 drugs has transformed obesity treatment discussions among both doctors and patients.
Some experts believe these medications may help reduce stigma around obesity by treating it more like a chronic medical condition rather than a personal failure.
At the same time, the drugs have sparked intense public interest because many users have shared dramatic weight-loss stories online.
Still, researchers caution that the medications are not simple miracle cures.
Some patients experience side effects such as nausea, vomiting, stomach pain, diarrhea, constipation, or fatigue. In many cases, patients may need to continue taking the drugs long term to maintain weight loss.
Meanwhile, bariatric surgery still remains one of the most effective treatments available for severe obesity and may provide greater long-term weight reduction for some patients.
Doctors emphasize that surgery and medications should not necessarily be viewed as competitors. Different patients may benefit from different treatment approaches depending on their health conditions, weight-loss goals, and medical history.
One especially important finding from the study was that obesity remains heavily undertreated overall.
More than 90% of people with obesity or diabetes in the study received neither bariatric surgery nor GLP-1 medication.
This highlights ongoing barriers to obesity care, including treatment cost, insurance restrictions, limited healthcare access, fear of side effects, and social stigma.
Researchers say healthcare systems may need to prepare for rapidly increasing demand for obesity medications in the coming years.
Insurance companies, doctors, and policymakers may also face difficult questions about long-term affordability because many GLP-1 medications are extremely expensive.
At the same time, experts warn that medication alone may not fully solve the obesity crisis. Healthy eating, physical activity, mental health support, and long-term lifestyle changes will likely remain important parts of treatment.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies that Mediterranean diet can reduce belly fat much better, and Keto diet could help control body weight and blood sugar in diabetes.
Source: JAMA Surgery study.
